Putting our region's cancer needs first

Merseyside & Cheshire

See the projects that we're currently funding in your region.

The cellular response to DNA damage: Ubiquitylation-dependant regulation of 8-oxoguanine DNA glycosylase (OGGI)

Dr Parsons          £114,670 / three years 


Characterisation of the endothelial cell surface molecule(s) responsible for galectin -3- induced secretion of metastasis-promoting cytokine

Dr Lu-Gang Yu, Prof Rhoses, Prof Beynon           £149,811 / three years 


The KRAS regulated kinase, DCLK1: downstream elements and their roles in cancer

Prof Clague, Prof Urbe          £185,303 /  three years 


Analysis of MAP4K3 function and regulation in cancer

Dr Lamb, Dr Eyers               £122,262


A phase lb study of pre-operative cisplatin and gemcitabine chemotherapy in patients with Borderline resectable Biliary tract cancer: BBC-01 study

Prof Palmer, Mr Jones, Mr Malik          £119,657


Determining ibrutinib’s potential to treat human leukaemias – novel uses for an exciting new Bruton’s tyrosine kinase (BTK) inhibitor

Prof MacEwan, Prof Pettitt, Dr Slupsky           £162,443 / three years 


Molecular mechanism of regulation of the cellular protein levels of endonuclease III homologue (NTH1), in response to DNA damage

Dr Parsons           £113,754 / three years 


Myofibroblast control of oesophageal squamous cancer invasion: role of chemerin

Prof Varro, Prof Beynon, Prof Dockray           £114,975 / two years 


Why are Ras isoforms not redundant? Characterising isoform-specific oncogenic Ras signalling networks

Prof Prior           £194,803 / three years 


Regulation of actin mediated endocytic recycling in invasive Her2 positive breast cancer

Dr Zech            £190,962 / three years 


Functional characterisation of the distinct complexes of MCL-1, an anti-apoptotic BCL-2 family member, in regulating apoptosis in cancer cells

Dr Varadarajan, Prof Cohen          £134,689 / three years 


Characterising the Bruton’s tyrosine kinase signalling nexus in leukaemia

Dr Slupsky, Prof Prior, Prof MacEwan          £185,950 / three years  


Optimising NK cell cytotoxicity and infiltration and global health

Dr Coombes, Dr Morgan             £133,823 / three years 


Targeting an Achilles’ heel of cancer: Debiquitylases as novel targets for centrosome decluttering and cancer-cell specific death

Dr Coulson          £189,049 / three years 


The NWCR Bioinformatics Fellowship

Dr Hammond      £176,632 / three years 


Exosome biogenesis: the role of sortilin in cancer biology

Dr Liloglou, Dr Wilson, Prof Coupland, Prof Clague, Dr Kalirai, Prof Field         £184,613 / three years 


Mechanistic investigation and risk: benefit analysis of the use of brusatol as a novel adjuvant for overcoming cisplatin resistance in bladder cancer

Dr Copple, Dr Hussain, Dr Goldring, Prof Park          £128,968 / two years 


The radiobiology of proton therapy

Dr Parsons         £186,096 / three years 


Development of novel multiplexable single-colour Ras GTPase sensors to compare spatio-temporal features of Ras signalling cascades with subcellular resolution

Dr Stagi, Prof Prior          £192,220 / three years 


Understanding the heterogeneity of chronic lymphocytic leukaemia through the elucidation of how genetic alterations influence protein expression at the whole genome level

Prof Pettitt, Dr Zhuang, Dr Kitteringham, Dr Jenkins, Prof Falciani, Prof Park          £194,420 / three years 


Phosphoproteomic analysis of the master centriole regulator Polo-like kinase 4 using target validated kinase inhibitors

Dr Patrick Eyers, Prof Claire Eyers, Dr Christopher Staples          £196,214 / three years 


S18‐phosphorylation controls catalytic activity of the cancer-associated deubiquitylase USP7: defining the implications for cancer biology and USP7 inhibitor therapy

Prof Judy Coulson, Dr Sarah Darling          £205,292 / three years


Investigating in-vivo resistance mechanisms to MEK inhibitors in uveal melanoma to enable novel combinatorial therapies

Dr Joseph Sacco, Prof Sarah Coupland, Dr Judy Coulson, Dr Patrick Eyers, Dr Helen Kalirai, Dr Sarah Lake          £131,189 / two years 


Gene edited reversal of FLT3-ITD mutations in acute myeloid leukaemia and its effect on chemotherapy resistance

Prof David J. MacEwan, Prof Richard E. Clark          £181,676 / three years 


The role of the ERK5 signalling axis in vemurafenib-resistant melanoma progression

Dr Cross, Mr Pritchard-Jones, Dr Tournier              £131,790 / two years 


Understanding the relationship between BCR signalling capacity and clonal behaviour in chronic lymphocytic leukaemia

Dr Kalakonda, Dr Slupsky, Prof Pettitt, Prof MacEwan, Prof Falciani          £195,288 / three years 


Novel therapeutic approches for personalised therapy of Head and Neck cancer 

Dr Shankar Varadarajan, Dr Joe Sacco, Dr Janet M Risk, Prof Gerald M Cohen          £192,243 / three years 


Evaluation of novel combination drug protocols for neuroblastoma using advanced imaging in a chick embryo model

Dr Violaine See, Prof Paul Losty          £117,382 / two years 


Forcing angiogenesis: Transcriptional control by integrin-dependent mechanotransduction during angiogenesis

Dr Mark Morgan, Dr Katarzyna Wolanska          £224,182 / three years 


Isolation and identification of the chromatin remodelling enzymes required for base excision repair

Dr Jason Parsons          £109,991 / three years 


Towards the clinical positioning of a first selective DUB inhibitor

Dr Sylvie Urbe, Prof Michael Clague, Dr Barry L Pizer, Dr Claire Heride          £141,569 / two years 


Non-canonical protein phosphorylation in human cancer cells

Prof Claire Eyers, Prof Pat Eyers, Dr Andrew Jones          £229,675 / three years 


Absolute quantitation of endogenous Ras isoform protein abundance: Does codon bias explain the predominance of KRAS mutations in cancer

Prof Ian Prior          £127,257 / two years 


Kinome profiling and mass cytometry as tools to detect rewiring of B cell receptor signalling in the malignant cells of chronic lymphocytic leukaemia patients taking ibrutinib

Dr J Slupsky, Prof Ian Prior          £217,307 / three years 


Integrating biomarkers to stratify adjuvant chemotherapy in pancreatic cancer patients

Dr William Greenhalf, Dr Dan Palmer, Dr Eithne Costello          £193,220 / three years 


Characterisation of the tumour- immune microenvironment in metastatic uveal melanoma

Dr Carlos Rogerio de Figueiredo, Prof Sarah Coupland            £132,434 / two years 


Function of stroma-derived gas6 in pancreatic cancer progression and metastasis

Dr Ainhoa Mielgo, Mr Robert Jones          £114,450 / three years 


Improving the biological response of proton beam therapy in head and neck cancer

Dr Jason Parsons          £202,129 / three years 


Tribbles pseudokinases: Analysis of cancer-associated signalling mechaniscHRISTIANMs

Prof Patrick Eyers, Dr Dominic Byrne, Prof Claire Eyers          £221,262 / three years 


The role of the ERK5 signalling axis in BRAF inhibitor-resistant melanoma progression

Dr Mike Cross, Dr Rowan Pritchard-Jones, Dr Cathy Tournier, Dr Emanuele Giurisato, Dr Harish Poptani, Prof Clare Eyers          £229,883 / three years 


Method optimisation of urine GC-MS analysis to predict dying in lung cancer patients

Dr Seamus Coyle, Professor John Ellershaw, Prof Chris Probert, Prof Mark Boyd          £33,899 / one year 


North West Cancer Research Centre 

The funding provides support for a Centre Administrator, a rolling PhD Studentship programme, the LCRIN Coordinator and support for the Research Development Fund. Funding was originally put in place in 2014 and this has now been extended through to the end of 2021.

£999,471 / four years